Neuland Laboratories Reports Decline in Key Financial Metrics for March 2025

Neuland Laboratories, a midcap player in the Pharmaceuticals & Biotechnology sector, has reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's financial landscape, with a revision in its score reflecting recent performance metrics. The Profit Before Tax less Other Income (PBT) for the quarter stands at Rs 31.84 crore, which shows a significant decline compared to the average of the previous four quarters. Similarly, the Profit After Tax (PAT) has also seen a downward adjustment, recorded at Rs 27.81 crore, again falling short of prior averages. Net Sales for the quarter reached Rs 328.36 crore, marking a decrease relative to the previous four-quarter average. Operating Profit has reached its lowest point in the last five quarters at Rs 51.07 crore, with the Operating Profit Margin also declining to 15.55%. Additionally, Earnings per Share (EPS) has dropped to Rs 21.56, indicating a reduction in profitability for shareholders. While Non-Operating Income has increased to Rs 7.46 crore, this rise may not be indicative of sustainable growth. Overall, Neuland Laboratories is experiencing a challenging financial period, as reflected in the adjustments to its evaluation metrics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.